We conducted this real-world, multicenter, retrospective, controlled study to compare the prognosis, efficacy, and safety of PD-1 and PD-L1 inhibitors in patients with ES-SCLC when combined with chemotherapy. This evidence concerns the gene CD274 and small cell lung carcinoma.